Fas counterattack in cholangiocarcinoma: A mechanism for immune evasion in human hilar cholangiocarcinomas

World Journal of Gastroenterology

Volumn 7, Issue 6, 2001, Pages 860-863

  Li, Z Y ^a   Zou, S Q ^a  

^a Tongji Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; FAS ANTIGEN; FAS LIGAND; MESSENGER RNA;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER IMMUNOLOGY; CANCER LOCALIZATION; CANCER TISSUE; CELL DEATH; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MALE; NICK END LABELING; PREVALENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 0035687313     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v7.i6.860     Document Type: Article

References (52)

1. Fas ligand induces apoptosis as a mechanism of immune privilege
2. A role for CD95 ligand in preventing graft rejection
3. The Fas death factor
4. Fas ligand mediates activation-induced cell death in human T lymphocytes
5. Expression of hepatocyte apoptosis and Fas/Fas L, in liver tissues of patients with hepatitis D
6. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer
7. CD95 ligand (FasL)-induced apoptosis is necessary for couneal allograft survival
8. The Fas counter-attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
9. Cholangiocarcinoma express Fas ligand and disable the Fas receptor
10. In situ detection of tumor infiltrating lymphocytes expressing protein and fas-ligand genes in human HCC
11. Induction of apoptosis in human gastric carcinoma cell line SGC-901 by anti Fas monoclonal antibody
12. The Fas/Fas-ligand system: A mechanism for immune evasion in human breast carcinomas
13. Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion
14. Expression of Fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer
15. Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance
16. Establishment of the extrahepatic cholangiocarcinoma cell line
17. Cholangiocarcinoma express Fas ligand and disable the Fas receptor
18. Fas ligand is constitutively secreted by prostate cancer cells in vitro
19. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas
20. Expression of Fas (CD95/Apo-1) and Fas ligand in lung cancer, its prognostic and predictive relevance
21. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer
22. Fas ligand: A sensor for DNA damage critical in skin cancer etiology
23. Fas and Fas-ligand expression in human pancreatic cancer
24. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma
25. Expression of Fas, FasL and HLA-DR in colon carcinoma
26. Fas/FasL expression of esophageal squamous cell carcinoma, dysplasia tissues and normal mucosa
27. Pathological and clinical studies on pancreatoplastoma
28. Angiogenesis and apoptosis in human hepatocellular carcinoma
29. Presence of Fas and Bcl-2 proteins in BEL-7404 human hepatoma cells
30. Clinical significance of Fasantigen expression in gastric carcinoma
31. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand
32. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo?
33. Reduction of tumorigenicity of SMMCa27721 hepatoma cells by vascular endothelial growth factor antisense gene therapy
34. Cloning of human cyclooxygenase 2 (COX) encoding gene and study of gastric cancer cell transfected with its antisense vector
35. Effect of combined anti Fas mAb and IFN-γ on the induction of apoptosis in human gastric carcinoma cell line SGC-7901
36. Abnormalities of p15 gene and protein expression in gastric cancers
37. Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas
38. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways
39. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis
40. p53 dependence of Fas induction and acute apoptosis in response to 5-Fluorouracil-Leucovorin in human colon carcinoma cell lines
41. A Fas-dependent component in 5-Fluorouracil/Leucovorin-induced cytotoxicity in colon carcinoma cells
42. Hepatocyte growth factor promotes cell survival from Fas-mediated cell death in hepatocellular carcinoma cells via Akt activation and Fas-death-inducing signaling complex suppression
43. Transduction of fas gene or bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs
44. Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells
45. Induction of murine hepatocyte death by membrane-bound CD95 (Fas/APO-1)-Ligand: Characterization of an in vitro system
46. Apoptosis is induced by anti-Fas antibody alone in cultured human keratinocytes
47. Levels of soluble Fas ligand in myocarditis
48. Fas antigen expression on CD34 + human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro
49. Expression and antitumor effects of TRAIL in human cholangiocarcinoma
50. Apoptosis and the liver: A mechanism of disease, growth regulation, and carcinogenesis
51. IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for up-regulation of Fas and FasL expression
52. T cell-mediated, INF-γ-facilitated rejection of murine B16 melanomas